Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, revealing his beneficial ownership of 1,539,134 shares of BioCardia, Inc. This stake represents 9.9% of the company’s common stock as of September 30, 2026. The disclosure is significant as it underscores Satterfield's continuing influence and investment in BioCardia, a key player in the biological products sector.

Background

BioCardia, Inc., identified by its Central Index Key (CIK) 0000925741, operates in the biological products industry, specifically focusing on products that do not involve diagnostic substances. The company is incorporated in Delaware and has its principal executive office located at 320 Soquel Way, Sunnyvale, California. BioCardia has undergone several name changes, with its most recent being from Tiger X Medical, Inc. in June 2011.

What the Filing Says

In the recent filing dated November 10, 2026, Satterfield disclosed that he holds 1,271,165 shares of common stock and has the right to acquire an additional 267,969 shares through warrants, subject to ownership limitations. The filing states, "The 1,539,134 shares of Common Stock reported... represent the 1,271,165 shares... and 267,969 shares of Common Stock issuable upon the exercise of Warrants." This ownership is capped at 9.99% due to regulatory restrictions.

Impact

This disclosure may have implications for both Satterfield and BioCardia. As a significant shareholder, Satterfield's actions and decisions may influence the company's strategic direction. Additionally, this filing could affect investor confidence in BioCardia, potentially impacting its market position within the biological products industry.

What's Next

The filing does not specify what actions may follow this disclosure, leaving future developments regarding Satterfield's ownership and BioCardia's strategy uncertain.